ORG-25935

Investigational

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C21H25NO3
Molecular Weight	339.4281
Optical Activity	UNSPECIFIED
Defined Stereocenters	2 / 2
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=CC=C2[C@H]([C@@H](CN(C)CC(O)=O)CCC2=C1)C3=CC=CC=C3

InChI

InChIKey=UEBBYLJZCHTLEG-UTKZUKDTSA-N

InChI=1S/C21H25NO3/c1-22(14-20(23)24)13-17-9-8-16-12-18(25-2)10-11-19(16)21(17)15-6-4-3-5-7-15/h3-7,10-12,17,21H,8-9,13-14H2,1-2H3,(H,23,24)/t17-,21+/m1/s1

HIDE SMILES / InChI

Molecular Formula	C21H25NO3
Molecular Weight	339.4281
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	2 / 2
E/Z Centers	0
Optical Activity	UNSPECIFIED

Description
Sources: https://www.ncbi.nlm.nih.gov/pubmed/25257291
Curator's Comment: description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/24525661 | https://www.ncbi.nlm.nih.gov/pubmed/22394471

Org 25935 (SCH 900435) is a synthetic drug developed by Organon International, which acts as a selective inhibitor of the glycine transporter GlyT-1. In human trial for prevention of relapse in alcohol-dependent patients in Org 25935 demonstrated no benefit over placebo in preventing alcohol relapse. Org 25935 was tested as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia, where it did not differ significantly from placebo in reducing negative symptoms or improving cognitive functioning. Clinical trials against panic disorder did not show any benefit compared to placebo.

CNS Activity

Originator

Approval Year

Targets

Primary Target	Pharmacology	Condition	Potency
Sodium- and chloride-dependent glycine transporter 1 5 Target ID: P48067 Gene ID: 6536.0 Gene Symbol: SLC6A9 Target Organism: Homo sapiens (Human) Sources: https://www.ncbi.nlm.nih.gov/pubmed/25257291	Inhibitor 8297
Sodium- and chloride-dependent glycine transporter 1 5 Target ID: CHEMBL1075303 Sources: http://www.europeanneuropsychopharmacology.com/article/S0924-977X(07)70764-2/fulltext	Inhibitor 8297		5.96 nM [IC50]

Conditions

Condition	Modality	Highest Phase	Product
Schizophrenia 298 Sources: https://www.ncbi.nlm.nih.gov/pubmed/24525661	Primary	Phase II 1132	Unknown Approved Use Unknown
Alcohol addiction 21 Sources: https://www.ncbi.nlm.nih.gov/pubmed/25257291	Primary	Phase II 1132	Unknown Approved Use Unknown
Panic disorder 22 Sources: https://www.ncbi.nlm.nih.gov/pubmed/22394471	Primary	Phase II 1132	Unknown Approved Use Unknown

C_max

Value	Dose	Analyte	Population
159 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748	8 mg 2 times / day multiple, oral dose: 8 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ORG-25935 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
165 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748	12 mg 2 times / day multiple, oral dose: 12 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ORG-25935 plasma	Homo sapiens population: UNKNOWN age: ADULT sex: FEMALE / MALE food status: UNKNOWN
243 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748	16 mg 2 times / day multiple, oral dose: 16 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ORG-25935 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN
72 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/17098748	4 mg 2 times / day multiple, oral dose: 4 mg route of administration: Oral experiment type: MULTIPLE co-administered:	ORG-25935 plasma	Homo sapiens population: UNHEALTHY age: ADULT sex: FEMALE / MALE food status: UNKNOWN

Doses

Dose	Population	Adverse events
16 mg 2 times / day multiple, oral (max) Highest studied dose Dose: 16 mg, 2 times / day Route: oral Route: multiple Dose: 16 mg, 2 times / day Sources: https://pubmed.ncbi.nlm.nih.gov/24525661 Page: p.194	unhealthy, 38.8± 11.0 n = 73 Health Status: unhealthy Condition: Schizophrenia Age Group: 38.8± 11.0 Sex: M+F Population Size: 73 Sources: https://pubmed.ncbi.nlm.nih.gov/24525661 Page: p.194	Sources: https://pubmed.ncbi.nlm.nih.gov/24525661 Page: p.194

Sourcing

Vendor/Aggregator	ID	URL
Axon MedChem	1563	https://www.axonmedchem.com/product/1563
MolPort	MolPort-042-665-714	https://www.molport.com/shop/molecule-link/MolPort-042-665-714
MuseChem	I008026	https://www.musechem.com/product/I008026.html
eMolecules	275059136	https://orderbb.emolecules.com/search/#?query=275059136
eMolecules	36367158	https://orderbb.emolecules.com/search/#?query=36367158

PubMed

Title	Date	PubMed
Evaluation of the glycine transporter inhibitor Org 25935 as augmentation to cognitive-behavioral therapy for panic disorder: a multicenter, randomized, double-blind, placebo-controlled trial.	2012 May	22394471

Patents

Sample Use Guides

In Vivo Use Guide

In clinical trial against schizophrenia Org 25935 was tested at 4 to 8 mg twice daily and 12 to 16 mg twice daily.

Route of Administration: Oral

In Vitro Use Guide

Compound inhibition of GlyT-1 activity was determined with a scintillation proximity assay (SPA) using radiolabeled glycine ([14C]-glycine) and Cytostar-T plates. ORG 25935 inhibited GlyT-1 with IC50 of 5.96 nM.

Substance Class	Chemical Created by `admin` on `Fri Dec 15 16:24:27 GMT 2023` Edited by `admin` on `Fri Dec 15 16:24:27 GMT 2023`
Record UNII	55L20667O4
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

ORG-25935

Common Name

English

SCH 900435

Code

English

ORG 25935

Code

English

GLYCINE, N-METHYL-N-(((1R,2S)-1,2,3,4-TETRAHYDRO-6-METHOXY-1-PHENYL-2-NAPHTHALENYL)METHYL)-

Systematic Name

English

SCH-900435

Code

English

ORG-25935 FREE BASE

Common Name

English

Code System Code Type Description

DRUG BANK

DB12220